Cargando…
Prevalence of Atrial Fibrillation in Patients with High CHADS(2)- and CHA(2)DS(2)VAS(c)-Scores: Anticoagulate or Monitor High-Risk Patients?
BACKGROUND: In patients with known atrial fibrillation (AF) different scores are utilized to estimate the risk of thromboembolic events and guide oral anticoagulation. Diagnosis of AF strongly depends on the duration of electrocardiogram monitoring. The aim of this study was to use established score...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282384/ https://www.ncbi.nlm.nih.gov/pubmed/25621351 http://dx.doi.org/10.1111/pace.12470 |
_version_ | 1782351126986752000 |
---|---|
author | Tischer, Tina S Schneider, Ralph Lauschke, Jörg Nesselmann, Catharina Klemm, Anke Diedrich, Doreen Kundt, Günther Bänsch, Dietmar |
author_facet | Tischer, Tina S Schneider, Ralph Lauschke, Jörg Nesselmann, Catharina Klemm, Anke Diedrich, Doreen Kundt, Günther Bänsch, Dietmar |
author_sort | Tischer, Tina S |
collection | PubMed |
description | BACKGROUND: In patients with known atrial fibrillation (AF) different scores are utilized to estimate the risk of thromboembolic events and guide oral anticoagulation. Diagnosis of AF strongly depends on the duration of electrocardiogram monitoring. The aim of this study was to use established scores to predict the prevalence of AF. METHODS: The CHADS(2)- (Congestive Heart failure, hypertension, Age >75 years, Diabetes, Stroke [doubled]) and CHA(2)DS(2)VASc-score (Congestive Heart failure, hypertension, Age ≥75 years [doubled], Diabetes, Stroke [doubled], Vascular disease, Age 65–74 years, Sex category [female sex]) was calculated in 150,408 consecutive patients, referred to the University Hospital of Rostock between 2007 and 2012. All factors constituting these scores and a history of AF were prospectively documented with the ICD-10 admission codes. RESULTS: Mean age of our study population was 67.6 ± 13.6 years with a mean CHADS(2)-score of 1.65 ± 0.92 and CHA(2)DS(2)VASc-score of 3.04 ± 1.42. AF was prevalent in 15.9% of the participants. The prevalence of AF increased significantly with every CHADS(2)- and CHA(2)DS(2)VASc-score point up to 54.2% in CHADS(2)-score of 6 and 71.4% in CHA(2)DS(2)VASc-score of 9 (P < 0.001). CONCLUSION: The prevalence of AF increases with increasing CHADS(2)- and CHA(2)DS(2)VASc-score. In intermediate scores intensified monitoring may be recommended. In high scores, thromboembolic complications occurred irrespective of the presence of AF and anticoagulant therapy may be initiated irrespective of documented AF. |
format | Online Article Text |
id | pubmed-4282384 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BlackWell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-42823842015-01-15 Prevalence of Atrial Fibrillation in Patients with High CHADS(2)- and CHA(2)DS(2)VAS(c)-Scores: Anticoagulate or Monitor High-Risk Patients? Tischer, Tina S Schneider, Ralph Lauschke, Jörg Nesselmann, Catharina Klemm, Anke Diedrich, Doreen Kundt, Günther Bänsch, Dietmar Pacing Clin Electrophysiol Electrophysiology BACKGROUND: In patients with known atrial fibrillation (AF) different scores are utilized to estimate the risk of thromboembolic events and guide oral anticoagulation. Diagnosis of AF strongly depends on the duration of electrocardiogram monitoring. The aim of this study was to use established scores to predict the prevalence of AF. METHODS: The CHADS(2)- (Congestive Heart failure, hypertension, Age >75 years, Diabetes, Stroke [doubled]) and CHA(2)DS(2)VASc-score (Congestive Heart failure, hypertension, Age ≥75 years [doubled], Diabetes, Stroke [doubled], Vascular disease, Age 65–74 years, Sex category [female sex]) was calculated in 150,408 consecutive patients, referred to the University Hospital of Rostock between 2007 and 2012. All factors constituting these scores and a history of AF were prospectively documented with the ICD-10 admission codes. RESULTS: Mean age of our study population was 67.6 ± 13.6 years with a mean CHADS(2)-score of 1.65 ± 0.92 and CHA(2)DS(2)VASc-score of 3.04 ± 1.42. AF was prevalent in 15.9% of the participants. The prevalence of AF increased significantly with every CHADS(2)- and CHA(2)DS(2)VASc-score point up to 54.2% in CHADS(2)-score of 6 and 71.4% in CHA(2)DS(2)VASc-score of 9 (P < 0.001). CONCLUSION: The prevalence of AF increases with increasing CHADS(2)- and CHA(2)DS(2)VASc-score. In intermediate scores intensified monitoring may be recommended. In high scores, thromboembolic complications occurred irrespective of the presence of AF and anticoagulant therapy may be initiated irrespective of documented AF. BlackWell Publishing Ltd 2014-12 2014-07-29 /pmc/articles/PMC4282384/ /pubmed/25621351 http://dx.doi.org/10.1111/pace.12470 Text en ©2014 The Authors. Pacing and Clinical Electrophysiology published by Wiley Periodicals, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Electrophysiology Tischer, Tina S Schneider, Ralph Lauschke, Jörg Nesselmann, Catharina Klemm, Anke Diedrich, Doreen Kundt, Günther Bänsch, Dietmar Prevalence of Atrial Fibrillation in Patients with High CHADS(2)- and CHA(2)DS(2)VAS(c)-Scores: Anticoagulate or Monitor High-Risk Patients? |
title | Prevalence of Atrial Fibrillation in Patients with High CHADS(2)- and CHA(2)DS(2)VAS(c)-Scores: Anticoagulate or Monitor High-Risk Patients? |
title_full | Prevalence of Atrial Fibrillation in Patients with High CHADS(2)- and CHA(2)DS(2)VAS(c)-Scores: Anticoagulate or Monitor High-Risk Patients? |
title_fullStr | Prevalence of Atrial Fibrillation in Patients with High CHADS(2)- and CHA(2)DS(2)VAS(c)-Scores: Anticoagulate or Monitor High-Risk Patients? |
title_full_unstemmed | Prevalence of Atrial Fibrillation in Patients with High CHADS(2)- and CHA(2)DS(2)VAS(c)-Scores: Anticoagulate or Monitor High-Risk Patients? |
title_short | Prevalence of Atrial Fibrillation in Patients with High CHADS(2)- and CHA(2)DS(2)VAS(c)-Scores: Anticoagulate or Monitor High-Risk Patients? |
title_sort | prevalence of atrial fibrillation in patients with high chads(2)- and cha(2)ds(2)vas(c)-scores: anticoagulate or monitor high-risk patients? |
topic | Electrophysiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282384/ https://www.ncbi.nlm.nih.gov/pubmed/25621351 http://dx.doi.org/10.1111/pace.12470 |
work_keys_str_mv | AT tischertinas prevalenceofatrialfibrillationinpatientswithhighchads2andcha2ds2vascscoresanticoagulateormonitorhighriskpatients AT schneiderralph prevalenceofatrialfibrillationinpatientswithhighchads2andcha2ds2vascscoresanticoagulateormonitorhighriskpatients AT lauschkejorg prevalenceofatrialfibrillationinpatientswithhighchads2andcha2ds2vascscoresanticoagulateormonitorhighriskpatients AT nesselmanncatharina prevalenceofatrialfibrillationinpatientswithhighchads2andcha2ds2vascscoresanticoagulateormonitorhighriskpatients AT klemmanke prevalenceofatrialfibrillationinpatientswithhighchads2andcha2ds2vascscoresanticoagulateormonitorhighriskpatients AT diedrichdoreen prevalenceofatrialfibrillationinpatientswithhighchads2andcha2ds2vascscoresanticoagulateormonitorhighriskpatients AT kundtgunther prevalenceofatrialfibrillationinpatientswithhighchads2andcha2ds2vascscoresanticoagulateormonitorhighriskpatients AT banschdietmar prevalenceofatrialfibrillationinpatientswithhighchads2andcha2ds2vascscoresanticoagulateormonitorhighriskpatients |